Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).

Authors

Frank A. Sinicrope

Mayo Clinic, Rochester, MN

Frank A. Sinicrope , Qian Shi , Hee Eun Lee , Nathan R. Foster , Steven R. Alberts , Thomas C. Smyrk

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial.

First Author: Frank A. Sinicrope

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Tumor-infiltrating lymphocytes and tumor budding refine prognostication in patients with low- and high-risk stage III colon cancers (NCCTG N0147)[Alliance].

First Author: Dan Sha

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

First Author: Frank A. Sinicrope

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147.

First Author: S. R. Alberts